Can Wegovy Cause Gallbladder Issues?

Wegovy has become a popular medication for weight management, helping many people achieve significant weight loss and improve their overall health. Its active ingredient, semaglutide, works by mimicking a naturally occurring hormone that regulates appetite, intake of food, and blood sugar levels. However, like any prescription medication, Wegovy can cause side effects, and some of them deserve particular attention.

In this article, we will look for an answer to the following question: “Can Wegovy cause gallbladder complications?” So, let’s take a closer look at the relationship between Wegovy and gallbladder wellbeing, the symptoms to watch for, and the steps that may help reduce potential risks.

How Does Wegovy (GLP-1 Medication) Affect the Gallbladder and Can It Cause a Gallbladder Disease?

To understand the connection between Wegovy and gallbladder problems, it helps to know a little about how the gallbladder works. The gallbladder is a small, pear-shaped organ located beneath the liver. Its primary function is to store and concentrate bile, a digestive fluid produced by the liver. When you eat, particularly foods containing fat, the gallbladder releases bile into the small intestine to help break down and absorb fats.

Wegovy belongs to a group of medications known as GLP-1 receptor agonists. It mimics glucagon-like peptide-1 (GLP-1), a hormone involved in appetite regulation and blood sugar control. By activating GLP-1 receptors, semaglutide helps:

• Reduce appetite and food cravings;
• Increase feelings of fullness after eating;
• Slow stomach emptying;
• Improve blood sugar regulation;
• Support weight loss by reducing overall calorie intake.

Although these effects can be beneficial, they may also influence the digestive system. Changes in food intake, weight, and gallbladder function can contribute to the development of gallstones.

There are two important factors to consider:

• Rapid weight loss: One of the most recognised risk factors for gallstones is losing weight quickly. When the body breaks down fat during rapid weight loss, the liver releases additional cholesterol into bile. If bile contains too much cholesterol, it can become supersaturated, allowing cholesterol crystals to form. Over time, these crystals may develop into gallstones. People taking Wegovy may experience substantial weight loss, particularly during the first months of treatment. This can increase their likelihood of developing gallstones;
• Changes in emptying of gallbladder: GLP-1 medications may also affect gallbladder motility and the way bile is released during digestion. Slower or less efficient emptying of gallbladder can encourage bile to remain in the gallbladder for longer, potentially contributing to stone formation. The exact mechanisms behind this relationship are still being investigated. Nevertheless, clinical evidence confirms that gallbladder complications occur more frequently in people taking Wegovy than in those receiving a placebo.

What Gallbladder Problems Can Wegovy Cause?

Wegovy is associated primarily with two types of gallbladder complications: cholelithiasis and cholecystitis. Although these conditions are related, they are not the same:

• Gallstones (cholelithiasis): Gallstones are hardened deposits that develop inside the gallbladder. They can vary considerably in size, ranging from tiny particles to larger stones. Most gallstones are made primarily of cholesterol, although some contain bilirubin, a substance produced when the body breaks down red blood cells. Gallstones do not always cause noticeable symptoms. Many people have them without knowing it, and they may only be discovered during an examination for an unrelated condition. However, problems can arise when a gallstone blocks one of the ducts that carries bile away from the gallbladder. This can cause sudden pain, digestive discomfort, and potentially more serious complications;
• Gallbladder inflammation (cholecystitis): Cholecystitis refers to inflammation of the gallbladder. It often develops when a gallstone becomes lodged in the cystic duct, preventing bile from draining properly. As bile accumulates, the gallbladder can become irritated and inflamed. If left untreated, acute cholecystitis may lead to infection, tissue damage, or other serious complications. Although gallstones are the most common cause, gallbladder inflammation can occasionally develop without them.

Other possible complications include bile duct obstruction and, in some cases, inflammation of the pancreas (pancreatitis). These conditions require prompt medical assessment.

How Common Are Gallbladder Problems with Wegovy?

While Wegovy offers a wide range of health benefits, it can also lead to several side effects, including gallbladder complications, although most people taking the medication will not develop serious gallbladder disease. Clinical trial data included in the prescribing information provide a clearer picture of the potential risk. Namely, among adults receiving injectable Wegovy for weight management, it is important to pay attention to the following information:

• Gallstones were reported in approximately 1.6% of patients, compared with 0.7% of those receiving a placebo;
• Cholecystitis was reported in approximately 0.6% of Wegovy-treated patients, compared with 0.2% of placebo-treated patients.

These figures demonstrate that gallbladder complications were more common among people receiving Wegovy, and the label notes that the rates were higher still in adolescents than in adults.

Importantly, the prescribing information also notes that the increased occurrence of acute gallbladder disease remained evident even after accounting for the amount of weight lost. This suggests that rapid weight loss alone may not explain the entire association.

The exact wording of the label: “Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in WEGOVY-treated patients than in placebo-treated patients, even after accounting for the degree of weight loss” (Wegovy Prescribing Information, Novo Nordisk, U.S. Food and Drug Administration label).

It is also worth remembering that clinical trial figures represent groups of participants, not an individual’s personal risk. Factors such as medical history, existing gallstones, weight-loss rate, and other health conditions may influence the likelihood of complications.

PLEASE NOTE
Among common adverse reactions associated with Wegovy are nausea, vomiting, and slowed digestion. Also, research on GLP-1 medications shows that the gallbladder risk is higher at higher doses and with longer use. If any severe pain (or, more precisely, sharp pain) occurs, a patient should contact a healthcare provider as soon as possible. Severe abdominal pain that spreads to the back can also signal pancreatitis, and in that case the prescribing information says to stop Wegovy promptly.

How Quickly Can a Wegovy Patient Develop Symptoms of Gallbladder Disease and What Are the Warning Signs of Gallbladder Risks?

Gallbladder problems can develop at different stages of Wegovy treatment. Some patients may experience symptoms within weeks or months, while others may develop complications after losing a significant amount of weight. The timing varies depending on individual risk factors, weight-loss speed, and existing gallbladder health. Because Wegovy can cause digestive side effects, such as nausea, vomiting, and abdominal discomfort, it is important to distinguish routine reactions from potential gallbladder issues. Common warning signs include:

• Upper right abdominal pain: Sudden or persistent discomfort beneath the right ribs, sometimes lasting several hours;
• Pain after meals: Particularly following fatty foods;
• Nausea and vomiting: Especially when persistent or accompanied by abdominal pain;
• Pain spreading to the back or right shoulder: A possible sign of gallbladder inflammation or gallstones;
• Fever and chills: Potential indicators of infection or inflammation;
• Jaundice: Yellowing of the skin or eyes, which may suggest bile duct obstruction;
• Dark urine and pale stools: Possible signs of impaired bile flow.

PLEASE NOTE
Severe or persistent abdominal pain, particularly when accompanied by fever, repeated vomiting, or jaundice, requires urgent medical evaluation. Even mild but recurring pain in the upper right abdomen should be discussed with a healthcare professional. Since gallbladder complications can resemble common Wegovy side effects, patients should never dismiss unusual or worsening symptoms as ordinary digestive discomfort.

Who Is More Likely to Develop Gallbladder Problems (Including Gallstone Risks) While Taking Wegovy?

Although Wegovy can increase the likelihood of gallbladder complications, certain people may already have a higher baseline risk. Potential risk factors include:

• Previous gallstones: People who have experienced gallstones before may be more susceptible to developing further complications;
• Rapid or substantial weight loss: Losing a significant amount of weight over a relatively short period can increase cholesterol concentrations in bile;
• Obesity: Excess body weight is independently associated with a higher risk of cholesterol gallstones;
• A family history of gallstones: Genetic factors can influence gallbladder function and the composition of bile;

• Older age: The likelihood of developing gallstones generally increases with age;
• Certain medical conditions: Diabetes, metabolic disorders, and some liver conditions may influence gallstone risk;
• Very low-calorie diets: Severely restricting calorie intake can interfere with normal gallbladder emptying and increase the likelihood of stone formation (in this regard, it is worth mentioning that GLP-1 medications such as Wegovy may also slow gallbladder emptying).

A meta-analysis of 76 randomised trials with more than 103,000 participants concluded that “use of GLP-1 RAs was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss” (He et al., JAMA Internal Medicine, 2022). In the weight-loss trials, the relative risk was more than twice that seen with placebo or other drugs.

Having one or more of these risk factors does not automatically mean someone cannot use Wegovy. However, they are important considerations when discussing treatment options with a healthcare provider.

Can You Prevent Gallbladder Problems While Taking Wegovy?

There is no guaranteed way to prevent gallstones during Wegovy treatment. However, certain lifestyle and treatment-related measures may help reduce the risk:

• Aim for gradual, sustainable weight loss: Although Wegovy can produce substantial weight reduction, losing weight as quickly as possible is not necessarily beneficial. Following the prescribed treatment schedule and maintaining realistic weight-loss goals can help avoid unnecessarily rapid changes;
• Maintain a balanced diet: A nutritious, balanced eating plan supports general digestive health. Include vegetables, fruits, whole grains, lean protein, and moderate amounts of healthy fats. Completely eliminating dietary fat is generally not advisable because some dietary fat helps stimulate normal gallbladder contraction;
• Stay hydrated: Drinking enough water supports normal bodily functions and helps maintain healthy digestion. While hydration alone cannot prevent gallstones, it is an important part of a balanced weight-management routine;
• Avoid extreme calorie restriction: Skipping meals regularly, following crash diets, or severely restricting food intake may increase gallstone risk. Instead, focus on sustainable eating habits that provide sufficient nutrients;
• Keep up with medical appointments: Regular communication with your healthcare provider allows potential side effects to be identified and addressed early. Discuss any previous gallbladder problems before starting treatment, and report new or persistent abdominal symptoms.

Prevention can lower the odds, but it cannot remove them. The label instructs prescribers: “Advise patients that substantial or rapid weight loss can increase the risk of gallbladder disease, but that gallbladder disease may also occur in the absence of substantial or rapid weight loss” (Wegovy Prescribing Information, Patient Counseling Information).

What Happens If You Develop Gallstones While Taking Wegovy?

A diagnosis of gallstone formation does not automatically mean that Wegovy treatment must be permanently discontinued. The appropriate approach depends on the symptoms, severity of the condition, and overall medical circumstances. If gallstones are suspected, a healthcare professional may recommend several investigations:

• Abdominal ultrasound is commonly the first-line imaging examination. It can identify gallstones, assess gallbladder inflammation, and detect certain abnormalities in the bile ducts;
• Blood tests may also be performed to assess liver function, inflammation, and other possible complications.

Depending on the findings, treatment options may include:

• Observation: Gallstones that do not cause symptoms may not require immediate treatment;
• Medication: Certain medicines can dissolve selected cholesterol gallstones, although treatment may take a long time and is not suitable for everyone;
• Surgery: Laparoscopic cholecystectomy, which involves removing the gallbladder through small incisions, is a common treatment for symptomatic gallstones;
• Hospital treatment: Acute cholecystitis or complications involving bile duct obstruction may require hospital care, antibiotics, or additional procedures.

If gallbladder disease is suspected, the decision to continue, pause, or discontinue Wegovy should be made with the prescribing healthcare professional. Patients should not independently change their medication dosage or attempt to manage potentially serious symptoms at home.

Is It Safe to Take Wegovy If You Have Had Your Gallbladder Removed or Plan to Undergo a Gallbladder Removal in the Nearest Future?

People who have had their gallbladder removed can generally still use Wegovy, provided their healthcare provider considers it appropriate. Gallbladder removal (cholecystectomy) does not prevent the liver from producing bile, which continues to flow directly into the small intestine. However, patients planning gallbladder surgery should discuss their Wegovy treatment with their surgeon and prescribing healthcare professional. They may need specific instructions about continuing or temporarily pausing the medication before surgery because semaglutide slows stomach emptying and may affect anaesthesia-related risks. Even after gallbladder removal, other digestive or bile duct complications can occur. Therefore, treatment decisions should always consider the patient’s medical history, surgical plans, and overall health.

Conclusion

To sum up, Wegovy can increase the risk of gallbladder issues, particularly gallstones and gallbladder inflammation. Although these complications are relatively uncommon, they are important potential side effects that patients and healthcare professionals should understand. Rapid weight loss, changes in bile composition, and alterations in gallbladder function may all contribute to this increased risk. The good news is that most people taking Wegovy do not develop serious gallbladder complications. Maintaining balanced eating habits, avoiding extreme weight-loss practices, and recognising warning signs can help support safer treatment. Most importantly, patients should work closely with their healthcare providers to monitor their progress and address any concerning symptoms promptly.

For healthcare professionals looking to expand their treatment offerings, FillerCloud offers a convenient online destination with a broad range of brand-name medical and cosmetic injectables, including dermal fillers and botulinum toxins. Explore the available selection, enjoy advantageous purchasing terms, and order professional-grade products with confidence.